About Ablynx
Ablynx is a Healthcare company based in Ghent (Belgium) founded in 2001, and was acquired by Sanofi in January 2018. It operates as a nanobodies for serious human diseases are discovered and developed. Ablynx has raised $86.33 million across 11 funding rounds from investors including Sanofi, Kbc and Gimv. Its focus areas include Diversified Pharmaceuticals and Drugs. Its competitors include Merck, Roivant Sciences, AbbVie, Gilead and Lilly and 5 more; 1 of its 10 listed competitors has raised funding.
Company details
Founded in 2001 in Ghent, Belgium, operations in the biopharmaceutical sector are focused on the discovery and development of Nanobodies, which are single-domain antibody fragments used as therapeutic proteins. These are targeted at conditions such as inflammation, hematology, oncology, and pulmonary diseases. Approximately 45 proprietary and partnered projects are maintained in the pipeline, with five Nanobodies currently in clinical development.
- Headquarters Ghent, Belgium
- Stage Public
- SectorsHealthcare
- Website ablynx.com
- Social LinkedIn Facebook YouTube
- Acquired by Sanofi (Jan 2018)
- Legal Name Ablynx
Apps and channels of Ablynx
its YouTube channel Sanofi has 33K subscribers and 30 videos.
Videos from Ablynx
The most watched videos on Ablynx's YouTube channel, Sanofi (33K subscribers). Click a video to play it here.
More on Sanofi.
Funding Insights of Ablynx
Ablynx has successfully raised a total of $86.33M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $82.67 million completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $86.33M
- Total Rounds 11
- Last Round Post-IPO — $82.67M
- First Round $4.91M
(Sep 2002)
- Investors Count 12
Latest 10 of 11 funding rounds of Ablynx with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $82.67M | Post-IPO | – | – | – |
| Aug 2014 | $2.81M | Grant | – | – | |
| Jun 2014 | $56.93M | Post-IPO | – | – | – |
| Feb 2013 | $41.21M | Post-IPO | – | – | – |
| Jul 2010 | $1.88M | Grant | – | – | |
| Feb 2010 | $1.63M | Grant | – | – | |
| Oct 2008 | $2.5M | Grant | – | – | |
| Sep 2007 | $2.68M | Grant | – | – | |
| Aug 2006 | $51.38M | Series C | – | Kbc, SR One | |
| Apr 2004 | $30.04M | Series B | – | Abingworth, Alta Partners |
13 investors in total: 13 institutional.
Investors in Ablynx
Ablynx has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Sanofi, Kbc and Gimv.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm | 1980 | gimv.com | Antwerp, Belgium | |
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Venture capital firm focused on healthcare companies | – | altapartners.com | Jackson, United States | |
A biotechnology venture capital firm investing in innovative science. | – | srone.com | - | |
Private equity and venture captial firm focused on healthcare sectors | – | gildehealthcare.com | Cambridge, United States | |
Sofinnova Partners is focused on life sciences and healthcare investments. | – | sofinnovapartners.com | Paris, France | |
Private equity and accelerator investments are directed toward multiple sectors. | – | riveancapital.com | Brussels, Belgium | |
Biotech funding, drug development support, and investment in life sciences. | – | sofinnova.com | - | |
A platform for online casino gaming in Belgium is provided. | – | iwt.be | Belgium | |
- | – | flandersbio.be | - |
Investor details for Ablynx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ablynx
5 dated milestones of Ablynx across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Ablynx is founded.
- Funding First funding round of $4.9M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $82.7M.
- Exit Acquired by Sanofi.
Competitors of Ablynx
Ablynx has 10 listed competitors in our database, 1 of them funded. They include Merck, Roivant Sciences, AbbVie, Gilead and Lilly, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| merck.com | 1891 | Kenilworth, United Kingdom | – | 781 | Pharmaceutical products are manufactured and marketed worldwide. | |
| roivant.com | 2014 | New York, United States | $1.3B | 662 | Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | |
| abbvie.com | 2012 | Chicago, United States | – | 8,667 | Biopharmaceutical research and drug development are conducted globally by AbbVie. | |
| gilead.com | 1987 | Foster, United States | – | 4,267 | Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | |
| lilly.com | 1876 | United States | – | 39,000 | Traditional pharmaceutical medicines are developed for multiple health fields. | |
| vrtx.com | 1989 | United States | – | 5,400 | Developer of drugs for the treatment of multiple disorders | |
| unither.com | 1998 | Silver Spring, United States | – | 1,168 | Treatments for chronic and life-threatening diseases are developed and commercialized. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| roche.com | 1896 | Basel, Switzerland | – | 2,382 | Pharmaceuticals and diagnostics kits are developed for various diseases. | |
| eisai.com | 1941 | Tokyo, Japan | – | 10,419 | Drugs for oncology and neurological disorders are developed by Eisai. |
Detailed competitors of Ablynx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ablynx
Websites that share an audience with Ablynx (ablynx.com).
Websites whose visitors overlap most with Ablynx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| tigenix.com | 100% | – | – | View details | |
| amriglobal.com | 82% | 680.7K | – | View details | |
| shire.com | 82% | 1.4K | #14,679,892 | View details | |
| hikma.com | 82% | 159K | #227,704 | View details | |
| themedicinescompany.com | 82% | – | – | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 22 similar websites and full traffic analytics for Ablynx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 22 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Ablynx (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ablynx
Complete news archive for Ablynx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ablynx
Ablynx was founded in 2001 and raised its 1st funding round 1 year after it was founded.
Ablynx is headquartered in Ghent, Belgium. It is registered at Ghent, East Flanders, Belgium.
Ablynx is a funded company, having raised a total of $86.33M across 11 funding rounds to date. The company's 1st funding round was a Series B of $30.04M, raised on Sep 2002.
Founded in 2001 in Ghent, Belgium, operations in the biopharmaceutical sector are focused on the discovery and development of Nanobodies, which are single-domain antibody fragments used as therapeutic proteins. These are targeted at conditions such as inflammation, hematology, oncology, and pulmonary diseases. Approximately 45 proprietary and partnered projects are maintained in the pipeline, with five Nanobodies currently in clinical development.
Ablynx's top competitors include Merck, Roivant Sciences and AbbVie.
Ablynx has 13 investors. Key investors include Sanofi, Kbc, Gimv, VIB, and Abingworth.
Ablynx operates through Ablynx.
Yes. Ablynx was acquired by Sanofi in January 2018.